Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2013

Open Access 01-12-2013 | Research article

Assessment of vaccine candidates for persons aged 50 and older: a review

Authors: Renske Eilers, Paul FM Krabbe, Ted GA van Essen, Anita Suijkerbuijk, Alies van Lier, Hester E de Melker

Published in: BMC Geriatrics | Issue 1/2013

Login to get access

Abstract

Background

The increasing life expectancy in most European countries has resulted in growth of the population 50 and older. This population is more susceptible to infectious diseases because of immunosenescence, co-morbidity and general frailty. Thus, to promote healthy aging, vaccination against vaccine-preventable-diseases could be one strategy. In addition to its possible individual benefits, vaccination may also yield social benefits, such as a lower overall cost of healthcare. Most European countries, however, offer only influenza vaccine although vaccines for pneumococcal disease, herpes zoster, pertussis, and hepatitis A are also available. Our aim is to review the knowledge of these vaccines for persons aged 50 and older and explore the arguments for expanding current vaccination programmes beyond just influenza.

Methods

The evaluation model of Kimman et al. was used to assess herpes zoster, pneumococcal disease, pertussis and hepatitis A in terms of four domains: pathogen, vaccine, disease outcomes and cost-effectiveness. The sources were Dutch surveillance systems, seroprevalence studies and the international literature.

Results

Herpes zoster, pneumococcal disease and pertussis are prevalent among persons aged 50 and older. Vaccines vary in effectiveness and have mild and self-limiting side effects. Vaccination against pneumococcal disease and pertussis causes adaptation of the responsible pathogen. For pertussis and hepatitis A, the vaccine is not registered specifically for the elderly population. Vaccination against herpes zoster and pertussis could improve quality of life, while vaccination against pneumococcal disease and hepatitis A prevents mortality. However, only vaccination against herpes zoster and pneumococcal disease appear to be cost-effective.

Conclusions

Vaccination can improve the health of the elderly population. As our review shows, however, the data are too incomplete to accurately judge its potential impact. More research is needed to determine how vaccination can most effectively improve the health of the growing population 50 years and older.
Appendix
Available only for authorised users
Literature
1.
Eurostat: Mortality and life expectancy statistics. 2011, Belgium: European Commission
2.
Eurostat: Healthy life years statistics. 2011, Belgium: European Commission
3.
European Commission: Europe in figures: Eurostat yearbook 2010. 2010, Luxemburg: European Union
4.
Mathei C, Vaes B, Wallemacq P, Degryse J: Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc. 2011, 59 (12): 2201-2208. 10.1111/j.1532-5415.2011.03719.x.CrossRefPubMed
5.
Yoshikawa TT: Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000, 30 (6): 931-933. 10.1086/313792.CrossRefPubMed
6.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, et al: Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007, 128 (1): 92-105. 10.1016/j.mad.2006.11.016.CrossRefPubMed
7.
World Health Organisation (WHO): WHO Vaccine Preventable Diseases Monitoring System. 2011, Geneva: World Health Organisation, 27-09-2011
8.
Michel JP, Chidiac C, Grubeck-Loebenstein B, Johnson RW, Lambert PH, Maggi S, Moulias R, Nicholson K, Werner H: Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Aging Clin Exp Res. 2009, 21 (3): 254-257.CrossRefPubMed
9.
Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE: Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006, 24 (22): 4769-4778. 10.1016/j.vaccine.2006.03.022.CrossRefPubMed
10.
National Health Council the Netherlands: The future of the national immunisation program: towards a program for all age groups. 2007, The Hague: National Health Council the Netherlands
11.
12.
Van Vliet JA: History of the notifications. Tijdschrift voor infectieziekten. 2009, 4 (2): 51-60.
13.
Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E: Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009, 49 (2): e23-29. 10.1086/600045.CrossRefPubMed
14.
De Melker HE, Conyn-van Spaendonck MA: Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect. 1998, 121 (3): 637-643. 10.1017/S0950268898001587.CrossRefPubMedPubMedCentral
15.
Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM: Pienter 2-Project: second research project on the protection against infectious diseases offered by the national immunization program in the Netherlands. 2009, Bilthoven: National Institute for Public Health and the Environment
16.
de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, Boot H: The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine. 2006, 24 (18): 3946-3952. 10.1016/j.vaccine.2006.02.017.CrossRefPubMed
17.
National Coordination Centre for Outbreak Management: Varicella- en herpeszostervirusinfection – chickenpox and shingles. B02. Edited by: Environment NIfPHa. 2005, Bilthoven: National Coordination Centre for Outbreak Management, last revised 2008
18.
Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI: Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011, 10 (8): 1143-1167. 10.1586/erv.11.99.CrossRefPubMed
19.
Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A: Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine. 2009, 27 (17): 2394-2401. 10.1016/j.vaccine.2009.01.127.CrossRefPubMed
20.
Palmu AA, Kaijalainen T, Saukkoriipi A, Leinonen M, Kilpi TM: Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects. Scand J Infect Dis. 2012, 44 (46): 433-8.CrossRefPubMed
21.
de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, Mollema L, Mooi FR, Berbers GA: Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One. 2010, 5 (12): e14183-10.1371/journal.pone.0014183.CrossRefPubMedPubMedCentral
22.
de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M: The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006, 53 (2): 106-113. 10.1016/j.jinf.2005.10.020.CrossRefPubMed
23.
Suijkerbuijk A, Lugnér A, van Pelt W, Wallinga J, Verhoef L, de Melker H, de Wit A: Assesing potential introduction of universal and targeted hepatitis A vaccination in the Netherlands. 2012, Bilthoven: Rijksinstituut voor Volksgezondheid en Millieu
24.
National Coordination Centre for Outbreak Management: Hepatitis A. B15. Edited by: Environment NIfPHa. 2003, Bilthoven: National Coordination Centre for Outbreak Management, last revised 2009
25.
Harpas R, Ortega-Sanchez IR, Seward JF: Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008, 57: 1-30.
26.
Plotkin SA, Orenstein WA, Offit PA: Vaccines. 2008, Philadelphia: Elsevier, 5
27.
National Coordination Centre for Outbreak Management: Pertussis. A37. Edited by: Environment NIfPHa. 2007, Bilthoven
28.
29.
Mertens PL, Stals FS, Schellekens JF, Houben AW, Huisman J: An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis. 1999, 18 (4): 242-247. 10.1007/s100960050271.CrossRefPubMed
30.
Perevoscikovs J Fau-Lucenko I, Lucenko I Fau-Magone S, Magone S Fau-Brila A, Brila A Fau-Curikova J, Curikova J: Community-wide outbreak of hepatitis A in Latvia, in 2008. 2008, Eurosurveillance, 1560-7917. Electronic
31.
Castkova J, Benes C: Increase in hepatitis A cases in the Czech Republic in 2008 - an update. Euro Surveill. 2009, 14 (3): 19091-PubMed
32.
Hrivniakova L, Slacikova M, Kolcunova S: Hepatitis A outbreak in a Roma village in eastern Slovakia, August-November 2008. Euro Surveill. 2009, 14 (3): 19099-
33.
Suijkerbuijk AW, Lugner AK, van Pelt W, Wallinga J, Verhoef LP, de Melker HE, de Wit GA: Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. Vaccine. 2012, 30 (35): 5199-205. 10.1016/j.vaccine.2012.06.014.CrossRefPubMed
34.
Costa-Mattioli M, Di Napoli A, Ferre V, Billaudel S, Perez-Bercoff R, Cristina J: Genetic variability of hepatitis A virus. J Gen Virol. 2003, 84 (Pt 12): 3191-3201.CrossRefPubMed
35.
Loparev VN, Rubtcova EN, Bostik V, Tzaneva V, Sauerbrei A, Robo A, Sattler-Dornbacher E, Hanovcova I, Stepanova V, Splino M, et al: Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. Virology. 2009, 383 (2): 216-225. 10.1016/j.virol.2008.10.026.CrossRefPubMed
36.
Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, et al: Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009, 15 (8): 1206-1213. 10.3201/eid1508.081511.CrossRefPubMedPubMedCentral
37.
Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E: Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007, 30 (6): 1158-1166. 10.1183/09031936.00034407.CrossRefPubMed
38.
Johnson R, McElhaney J, Pedalino B, Levin M: Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007, 11 (Suppl 2): S43-48.CrossRefPubMed
39.
Schaffner W: Update on vaccine-preventable diseases: are adults in your community adequately protected?. J Fam Pract. 2008, 57 (4 Suppl)): S1-11. quiz S12PubMed
40.
Arnou R, Fiquet A, Thomas S, Sadorge C: Immunogenicity and safety of ZOSTAVAX(R) approaching expiry potency in individuals aged >/=50 years. Hum Vaccin. 2011, 7 (10): 1060-1065. 10.4161/hv.7.10.16480.CrossRefPubMedPubMedCentral
41.
Schmader K, Gnann JW, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008, 197 (Suppl 2): S207-215.CrossRefPubMed
42.
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010, 182 (16): 1731-1736.CrossRefPubMedPubMedCentral
43.
Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004, 39 (3): 342-348. 10.1086/421942.CrossRefPubMed
44.
Schaffner W, Rehm SJ, File TM: Keeping our adult patients healthy and active: the role of vaccines across the lifespan. Phys Sportsmed. 2010, 38 (4): 35-47.CrossRefPubMed
45.
van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010, 10: 237-10.1186/1472-6963-10-237.CrossRefPubMedPubMedCentral
46.
van Gageldonk-Lafeber Ab Fau -Bogaerts MAH, Bogaerts Ma Fau -Verheij RA, van der Verheij Ra Fau -Sande MAB, van der Sande MA: Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. Epidemiology and infection. 2009, 1469-4409. Electronic
47.
Schouls LM, de Greeff SC: What is pneumococcal infection and what is the prevalence?. Volksgezondheid Toekomst Verkenning (Dutch). Edited by: Compass NPH. 2010, Bilthoven: National Institute for Public Health and Environment
48.
Rozenbaum MH, Hak E, van der Werf TS, Postma MJ: Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands. Clin Ther. 2010, 32 (8): 1517-1532. 10.1016/j.clinthera.2010.06.016.CrossRefPubMed
49.
de Greeff SC, Lugner AK, van den Heuvel DM, Mooi FR, de Melker HE: Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine. 2009, 27 (13): 1932-1937. 10.1016/j.vaccine.2009.01.106.CrossRefPubMed
50.
De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville Fradet M, Rochette L, Halperin SA: Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000, 182 (1): 174-179. 10.1086/315648.CrossRefPubMed
51.
Haagsma JH, van der Zanden BP, Tariq L, van Pelt W, van Duynhoven YTPH, Havelaar AH: Disease burden and costs of selected foodborne pathogens in the Netherlands, 2006. 2009, Bilthoven: National institute for public health and environment
52.
53.
Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M: Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012, 30 (12): 2047-2050. 10.1016/j.vaccine.2012.01.045.CrossRefPubMed
54.
Bianco E, De Masi S, Mele A, Jefferson T: Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Dig Liver Dis. 2004, 36 (12): 834-842. 10.1016/j.dld.2004.07.014.CrossRefPubMed
55.
Farmaceutisch Kompas: Pneumococcal vaccine. 2006, Diemen: College voor Zorgverzekeringen
56.
CDC: FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2011, 60: 1279-1280.
57.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352 (22): 2271-2284. 10.1056/NEJMoa051016.CrossRefPubMed
58.
Schmader Ke Fau -Johnson GR, Johnson Gr Fau-Saddier P, Saddier P Fau-Ciarleglio M, Ciarleglio M Fau-Wang WWB, Wang Ww Fau-Zhang JH, Zhang Jh Fau-Chan ISF, Chan Is Fau-Yeh S-S, Yeh Ss Fau -Levin MJ, Levin Mj Fau -Harbecke RM, Harbecke Rm Fau -Oxman MN, et al: Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of American Geriatrics Society. 2010, 1532-5415. Electronic
59.
Oxman MN: Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010, 51 (2): 197-213. 10.1086/653605.CrossRefPubMed
60.
Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al: Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008, 66 (9): 378-383.PubMed
61.
Moberley S, Holden J, Tatham David P, Andrews Ross M: Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews. 2008, Chichester, UK: John Wiley & Sons, Ltd
62.
Zimmerman RK: If pneumonia is the “old man’s friend”, should it be prevented by vaccination? An ethical analysis. Vaccine. 2005, 23 (29): 3843-3849. 10.1016/j.vaccine.2005.01.158.CrossRefPubMed
63.
Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, et al: Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006, 43 (2): 151-157. 10.1086/504803.CrossRefPubMed
64.
Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, et al: Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005, 353 (15): 1555-1563. 10.1056/NEJMoa050824.CrossRefPubMed
65.
Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O: Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: A sub-analysis of four trials. Vaccine. 2011, 29 (35): 5932-5939. 10.1016/j.vaccine.2011.06.049.CrossRefPubMed
66.
Wendelboe AM, Van Rie A, Salmaso S, Englund JA: Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005, 24 (5 Suppl): S58-61.CrossRefPubMed
67.
D’Acremont V, Herzog C, Genton B: Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med. 2006, 13 (2): 78-83. 10.1111/j.1708-8305.2006.00001.x.CrossRefPubMed
68.
Nothdurft HD: Hepatitis A vaccines. Expert Rev Vaccines. 2008, 7 (5): 535-545. 10.1586/14760584.7.5.535.CrossRefPubMed
69.
Sanford M, Keating GM: Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010, 27 (2): 159-176. 10.2165/10489140-000000000-00000.CrossRefPubMed
70.
Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al: A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine. 2011, 29 (32): 5195-5202. 10.1016/j.vaccine.2011.05.031.CrossRefPubMed
71.
Weston WM, Chandrashekar V, Friedland LR, Howe B: Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009, 5 (12): 858-866.CrossRefPubMed
72.
Andre F, Van Damme P, Safary A, Banatvala J: Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines. 2002, 1 (1): 9-23. 10.1586/14760584.1.1.9.CrossRefPubMed
73.
Pham H, Geraci SA, Burton MJ: Adult immunizations: update on recommendations. Am J Med. 2011, 124 (8): 698-701. 10.1016/j.amjmed.2010.07.032.CrossRefPubMed
74.
75.
Millier A, Aballea S, Annemans L, Toumi M, Quilici S: A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoecon Outcomes Res. 2012, 12 (1): 71-94. 10.1586/erp.11.94.CrossRefPubMed
76.
Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA: Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007, 32 (3): 186-193. 10.1016/j.amepre.2006.10.016.CrossRefPubMed
77.
Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA: Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011, 68 (4): 322-330. 10.1016/j.maturitas.2011.01.011.CrossRefPubMed
78.
National Health Council the Netherlands: Influenza vaccination: revision of the indication. 2007, The Hague: National Health Council the Netherlands
79.
Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF: The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009, 28 (11): 954-959. 10.1097/INF.0b013e3181a90b16.CrossRefPubMed
80.
Lu PJ, Euler GL, Jumaan AO, Harpaz R: Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009, 27 (6): 882-887. 10.1016/j.vaccine.2008.11.077.CrossRefPubMed
Metadata
Title
Assessment of vaccine candidates for persons aged 50 and older: a review
Authors
Renske Eilers
Paul FM Krabbe
Ted GA van Essen
Anita Suijkerbuijk
Alies van Lier
Hester E de Melker
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2013
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/1471-2318-13-32

Other articles of this Issue 1/2013

BMC Geriatrics 1/2013 Go to the issue

Research article

Older adults with acquired brain injury: a population based study

Research article

Prevalence and correlates of dizziness in community-dwelling older people: a cross sectional population based study

Research article

Physical activity for people with dementia: a scoping study

Research article

Prospective association of the SHARE-operationalized frailty phenotype with adverse health outcomes: evidence from 60+ community-dwelling Europeans living in 11 countries

Research article

The minimal clinically important difference of six-minute walk in Asian older adults

Research article

Pilot comparative effectiveness study of surface perturbation treadmill training to prevent falls in older adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits